Pacesetter, Inc.

St. Jude Medical, Cardiology Division, Inc.

Tc1 LLC

Abbott Diabetes Care Inc.

St. Jude Medical International Holding S.a.r.l.

Yelena Nabutovsky

Gene A Bornzin

Fujian Qu

Hoda Razavi

Taraneh Ghaffari Farazi

Kyungmoo Ryu

Edward Karst

Stuart Rosenberg

John W Poore

Riddhi Shah

Cecilia Qin Xi

Anders Bjorling

Alex C Soriano

Dan E Gutfinger

Jong Gill

Kjell Noren

Brian Jeffrey Wenzel

Jennifer Rhude

Ryan Rooke

William Hsu

Neal L Eigler

Rahul Kumar Agarwal

James S Whiting

Allen J Keel

Rupinder Bharmi

Luke C McSpadden

Edith Merle Arnold

Julie Prillinger

Jenner Joseph

Lok Man Chu

Caroline D Jordan

Allison Connolly

Xiaoyi Min

Steve Koh

Eric Falkenberg

Nima Badie

Cyrille Casset

Annapurna Karicherla

Chunlan Jiang

Kritika Gupta

Lalit Venkatesan

Melanie Goodman Keiser

Nirav Dalal

Richard Samade

Brian Wisnoskey

Gary Cranke

Prashant Dinesh

Mark W Kroll

Dorin Panescu

Wenbo Hou

Laurence S Sloman

Sheldon Williams

Buehl E Truex

Andreas Blomqvist

Carl Lance Boling

Rose Province

Weiqun Yang

Alexander Kent

Mihir Naware

Avi Fischer

Rodney J Hawkins

Rohan More

Kevin Wilson

Gregory J Roberts

Jennifer M Joseph

Matthew S D Kerr

Sergio Richter

Philipp Sommer

Rafael Donnay

Adam Klonecke

Rahul Agarwal

Blood pump systems include a left ventricular assist device that is controlled to inhibit onset or worsening of right ventricular failure. A blood pump system includes a left ventricular assist device, a pulmonary artery pressure sensor, and a controller. The pulmonary artery pressure sensor is configured for generating a pressure signal indicative of a blood pressure in the pulmonary artery of the patient. The controller is configured to control operation of the left ventricular assist device, process the pressure signal to generate pulmonary artery pressure data indicative of right ventricular afterload of the patient, and adjust at least one operating parameter of the left ventricular assist device based on the pulmonary artery pressure data to reduce a deviation between the right ventricular afterload of the patient and a target right ventricular afterload for the patient.

Methods and systems for controlling a left ventricular assist device

A method of treatment of a type 2 diabetic patient includes selecting a type 2 diabetic patient having a predetermined comorbidity for treatment, initiating a continuous glucose monitor regimen for the selected type 2 diabetic patient, wherein after six months of initiation of the continuous glucose monitor regimen, a rate of hospitalization for a predetermined diagnostic category of the selected patient having the predetermined comorbidity is reduced by at least 12% relative to an average rate of hospitalization for the predetermined diagnostic category of selected patients having the predetermined comorbidity without the continuous glucose monitor regimen.

Systems, devices, and methods for analyte monitoring and benefits thereof

The present invention is generally related to methods and systems for preventing onset or worsening of RHF in patients with implanted ventricular assist devices. More particularly, the present invention relates to identifying patients at risk for RHF following implantation of a ventricular assist device based on pulmonary artery pressure measurement and/or trends and adjusting a pump operating parameter to prevent or reduce the onset or worsening of RHF in such patients, improve patient outcomes, or reduce mortality risks associated with VAD implantation. In particular, a pump operating parameter may be adjusted to reduce or minimize particularly high pressure loads on a patient's heart or amount of time the patient is exposed to such high pressure loads following implantation.

Methods for controlling a left ventricular assist device

Computer implemented methods and systems are provided for automatically determining capture thresholds for an implantable medical device equipped for cardiac stimulus pacing using a multi-pole left ventricular (LV) lead. The methods and systems measures a base capture threshold for a base pacing vector utilizing stimulation pulses varied over at least a portion of an outer test range. The base pacing vector is defined by a first LV electrode provided on the LV lead and a second electrode located remote from an LV chamber. The methods and systems designate a secondary pacing vector that includes the first LV electrode and a neighbor LV electrode provided on the LV lead. The methods and systems further define an inner test range having secondary limits based on the base capture threshold, wherein at least one of the limits for the inner test range differs from a corresponding limit for the outer test range. The methods and systems measure a secondary capture threshold associated with the secondary pacing vector utilizing stimulation pulses varied over at least a portion of the inner test range.

Method and system to determine capture thresholds

Controllers and methods for heart treatments are disclosed herein. The controller can include a communication module that can send and receive data from heart therapy devices. The controller can include memory including stored instruction. The controller can include a processor. The processor can receive a signal of an impending electrical treatment at a processor. The processor can determine a current operating parameter of a blood pump communicatingly coupled with the processor. The processor can determine an adjustment to the operating parameter of the blood pump to affect an impedance of heart tissue to be affected by the impending electrical treatment. The processor can control the blood pump according to the adjustment to the operating parameter of the blood pump.

Coordinated ventricular assist and cardiac rhythm management devices and methods

Baseline BiV pacing is delivered and a corresponding baseline BiV efficacy score is determined. Intrinsic AV conduction is allowed and an intrinsic AV conduction interval is determined. BiV fusion pacing is delivered and a corresponding efficacy score is determined, for each of a plurality of different paced AV delays, each determined based on the intrinsic AV conduction interval and a different negative hysteresis delta. The baseline BiV pacing is selected for delivery during a period of time if the baseline BiV efficacy score is better than all of the efficacy scores. BiV fusion pacing is selected for delivery during the period of time, using one of the plurality of different paced AV delays for which a corresponding efficacy score was determined, if the efficacy score corresponding to at least one of the plurality of different paced AV delays is better than the baseline BiV efficacy score.

Methods and systems for selectively delivering different types of bi-ventricular pacing

Systems, devices and methods described herein can be used to monitor and treat cardiovascular disease, and more specifically, can be used to determine heart rate (HR), determine respiration rate (RR) and classify cardiac rhythms based on atrial intracardiac electrogram (IEGM) and atrial pressure (AP) signals. The atrial IEGM and AP signals are subject to spectrum transforms to obtain an atrial IEGM frequency spectrum and an AP frequency spectrum. Based on peaks in the atrial IEGM and AP frequency spectrums measures of HR and RR are determined, and arrhythmias are detected and/or arrhythmia discrimination is performed.

Systems and methods to determine HR, RR and classify cardiac rhythms based on atrial IEGM and atrial pressure signals

A fully implantable trial neurostimulation system for implant within a patient is provided that includes one or more leads equipped to deliver neurostimulation to patient tissues under the control of a trial neurostimulation control device designed as a capsule for removable implant within the patient. The control capsule is provided with minimal components to power and control the delivery of neurostimulation during a trial evaluation period and is shaped and configured to facilitate removal from the patient following completion of the trial period. In some examples, both the lead and the trial control capsule are removed from the patient following the trial period for replacement with a chronic or long-term neurostimulation system (assuming further neurostimulation is warranted.) In other examples, the lead remains within the patient and the trial control capsule is replaced with a long-term neurostimulation controller device. Various minimally-intrusive implantation procedures are also described.

Fully implantable trial neurostimulation system configured for minimally-intrusive implant/explant

The present disclosure provides systems and methods for integrating cardiac resynchronization therapy (CRT) and temporary induced dyssynchrony (TID) therapy. An implantable cardiac device includes one or more pulse generators coupled to a plurality of electrodes, and a controller communicatively coupled to the one or more pulse generators and configured to cause the one or more pulse generators to apply a combination of CRT and TID therapy to a patient's heart via the plurality of electrodes in accordance with at least one protocol.

Systems and methods for integrating temporary induced dyssynchrony therapy with cardiac resynchronization therapy

The present disclosure provides a spinal cord stimulation (SCS) system. The system includes at least one SCS lead including a lead body, at least one distal electrode located at a distal end of the lead body, the at least one distal electrode configured to apply electrical stimulation to a stimulation target of a patient, and a pain reduction assembly coupled to the lead body and configured to reduce post-operation pain at an incision site associated with implantation of the at least one SCS lead. The system further includes a pulse generator coupled to the at least one SCS lead and configured to control electrical stimulation delivered to the patient via the at least one SCS lead.

Systems and methods for reducing pain during spinal cord stimulation trial

Systems and methods to determine HR, RR, and classify cardiac rhythms based on atrial IEGM and atrial pressure signals

A method and system are provided for assigning map points to anatomical segments of a heart. The method and system utilize an intravascular mapping tool configured to be inserted into at least one of the endocardial or epicardial space. The mapping tool is maneuvered to select locations proximate to surfaces of the heart, while collecting map points at the select locations to form a ROI data set. The method and system store the ROI data set in a data storage and defines apical, basal and circumferential landmarks within the ROI data set. The method and system automatically calculate circumferential and longitudinal segment boundaries, associated with wall segments of the heart, based on the apical, basal and circumferential landmarks. The method and system automatically assign segment identifiers (IDs) to the map points based on locations of the map points relative to the circumferential and longitudinal boundaries, the segment IDs associated with wall segments of the heart.

Method and system to automatically assign map points to anatomical segments and determine mechanical activation time

The present disclosure provides systems and methods for providing temporary induced dyssynchrony (TID) therapy to patients with atrial tachycardia. An implantable cardiac device includes a pulse generator coupled to a plurality of electrodes, and a controller communicatively coupled to the pulse generator and configured to cause the pulse generator to apply TID therapy to a patient's heart via the plurality of electrodes, determine that the patient's heart is experiencing atrial tachycardia, and adjust at least one parameter of the TID therapy based on the determination.

Systems and methods for providing temporary induced dyssynchrony therapy to patients with atrial tachycardia

Baseline BiV pacing is delivered and a corresponding baseline BiV efficacy score is determined. Intrinsic AV conduction is allowed and an intrinsic AV conduction interval is determined. BiV fusion pacing is delivered and a corresponding NAVH efficacy score is determined, for each of a plurality of different paced AV delays, each determined based on the intrinsic AV conduction interval and a different negative hysteresis delta. The baseline BiV pacing is selected for delivery during a period of time if the baseline BiV efficacy score is better than all of the NAVH efficacy scores. BiV fusion pacing is selected for delivery during the period of time, using one of the plurality of different paced AV delays for which a corresponding NAVH efficacy score was determined, if the NAVH efficacy score corresponding to at least one of the plurality of different paced AV delays is better than the baseline BiV efficacy score.

Growing community of inventors

Mountain View, CA, United States of America

Yelena Nabutovsky